MAP7D1: A Potential Drug Target and Biomarker (G55700)

Target Name: MAP7D1

NCBI ID: G55700

MAP7D1

MAP7D1: A Potential Drug Target and Biomarker

MAP7D1 (MA7D1_HUMAN), a gene located on chromosome 18, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

MAP7D1 is a gene that encodes a protein known as MA7D1, which is a member of the immune system's MAS-associated protein family 7 (MAP7D1 family). This protein plays a critical role in the development and maintenance of immune tolerance and has been implicated in a number of diseases.

One of the most promising aspects of MAP7D1 is its potential as a drug target. The MAP7D1 protein has been shown to be overexpressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, MAP7D1 has been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

MAP7D1 has also been linked to autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the body's immune system attacking itself, leading to inflammation and damage to the body's tissues.

Despite these promising findings, more research is needed to fully understand the role of MAP7D1 in disease. One of the main challenges in studying MAP7D1 is its expression and function in different tissues and organisms. However, researchers are actively working to overcome these challenges and to understand the full potential of MAP7D1 as a drug target and biomarker.

In addition to its potential as a drug target, MAP7D1 has also been identified as a potential biomarker for several diseases. For example, researchers have shown that levels of MAP7D1 protein are elevated in the blood and urine of individuals with rheumatoid arthritis, a common autoimmune disorder. Additionally, MAP7D1 has been shown to be elevated in the spinal fluid of individuals with multiple sclerosis, another autoimmune disease.

These findings suggest that MAP7D1 could be a useful biomarker for monitoring the effectiveness of anti-inflammatory treatments for these diseases. Additionally, since MAP7D1 is overexpressed in a variety of diseases, it could also be a useful target for new therapies that target the immune system.

In conclusion, MAP7D1 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in disease and to develop new treatments based on its properties. However, the potential of MAP7D1 as a drug target and biomarker is an exciting area of research that could have significant implications for the treatment of a variety of diseases.

Protein Name: MAP7 Domain Containing 1

The "MAP7D1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP7D1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets